// App-Quantinova.ai

2231 : Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings

Researchers

Presenter

  • John F. Seymour

Principal Investigators

  • John G. Gribben

  • Matthew S. Davids

  • Anthony Mato

  • Jeff P Sharman

  • Aimee Cyr

  • Cynthia Bartkus

  • German Pena

  • Michelle Boyer

  • Simon Sharmokh

  • Tanya S Rosenberg

  • William G. Wierda

Medical Centers

  • Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, Melbourne, Victoria, Australia

  • Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom

  • Dana-Farber Cancer Institute, Boston, MA

  • University of Pennsylvania, Philadelphia, PA

  • Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR

  • AbbVie, Inc., North Chicago, IL

  • Genentech, Inc., South San Francisico, CA

  • AbbVie, Inc., North Chicago, IL

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • Australia

  • United Kingdom

  • United States

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Tumor lysis syndrome

Biomarkers

  • RNA-binding protein FUS/TLS

Drug/Treatment

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved